Skip to main content
SpringerLink
Log in

Association between lower plasma adiponectin levels and higher plasma thrombin generation parameters in men with type 2 diabetes: role of plasma triglycerides

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Objective

Previous studies showed a significant association between lower plasma adiponectin levels and higher risk of adverse cardiovascular outcomes in patients with and without type 2 diabetes mellitus (T2DM). Presently, it is uncertain whether lower plasma adiponectin levels are associated with greater plasma thrombin generation in patients with T2DM.

Patients and methods

We studied 82 middle-aged men with non-insulin-treated T2DM [mean age ± SD: 64.1 ± 8 years; median duration of diabetes: 12.5 (inter-quartile range 6–19) years; mean hemoglobin A1c 7.0 ± 0.7%], consecutively attending our diabetes outpatient service over a 6-month period. Using the newly developed fully automated thrombin generation analyzer ST Genesia®, we measured the plasma parameters lag time (LT), time to peak (TP), peak height (PH) and endogenous thrombin potential (ETP) in all participants.

Results

In univariable linear regression analyses, lower plasma adiponectin levels were significantly associated with higher plasma thrombin generation parameters, as reflected by higher values of PH (Pearson’s r coefficient = − 0.228, p = 0.039) and EPT (r = − 0.293, p = 0.007). Plasma adiponectin levels were not significantly associated with other thrombin generation parameters (LT and TP). Notably, the significant associations of plasma adiponectin levels with thrombin PH and EPT values persisted after adjustment for age and adiposity measures, but they were lost after additional adjustment for plasma triglycerides.

Conclusion

Our findings show for the first time the existence of a significant association between lower levels of plasma adiponectin and greater plasma thrombin generation (as assessed by the ST Genesia® analyzer) in men with non-insulin-treated T2DM, which appears to be largely mediated by plasma triglycerides.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF (1995) A novel serum protein similar to c1q, produced exclusively in adipocytes. J Biol Chem 270:26746–26749

    Article  CAS  Google Scholar 

  2. Achari AE, Jain SK (2017) Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci 18(6):1321. https://doi.org/10.3390/ijms18061321

  3. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB (2006) Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 8:264–280

    Article  CAS  Google Scholar 

  4. Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L, Falezza G (2006) Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 64:679–683

    Article  CAS  Google Scholar 

  5. Ebrahimi-Mamaeghani M, Mohammadi S, Arefhosseini SR, Fallah P, Bazi Z (2015) Adiponectin as a potential biomarker of vascular disease. Vasc Health Risk Manag 11:55–70

    PubMed  PubMed Central  Google Scholar 

  6. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y, Osaka CAD Study Group (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85–89

    Article  CAS  Google Scholar 

  7. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B (2007) Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 92:571–576

    Article  CAS  Google Scholar 

  8. Hashimoto N, Kanda J, Nakamura T, Horie A, Kurosawa H, Hashimoto T, Sato K, Kushida S, Suzuki M, Yano S, Iwai R, Takahashi H, Yoshida S (2006) Association of hypoadiponectinemia in men with early onset of coronary heart disease and multiple coronary artery stenoses. Metabolism 55:1653–1657

    Article  CAS  Google Scholar 

  9. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730–1737

    Article  CAS  Google Scholar 

  10. Yang L, Li B, Zhao Y, Zhang Z (2019) Prognostic value of adiponectin level in patients with coronary artery disease: a systematic review and meta-analysis. Lipids Health Dis 18:227

    Article  CAS  Google Scholar 

  11. Kalz J, ten Cate H, Spronk HM (2014) Thrombin generation and atherosclerosis. J Thromb Thrombolysis 37:45–55

    Article  CAS  Google Scholar 

  12. Loeffen R, Spronk HM, ten Cate H (2012) The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost 10:1207–1216

    Article  CAS  Google Scholar 

  13. Salvagno GL, Favaloro EJ, Demonte D, Gelati M, Poli G, Targher G, Lippi G (2019) Influence of hypertriglyceridemia, hyperbilirubinemia and hemolysis on thrombin generation in human plasma. Clin Chem Lab Med 57:1784–1789

    Article  CAS  Google Scholar 

  14. Tripodi A (2016) Thrombin generation assay and its application in the clinical laboratory. Clin Chem 62:699–707

    Article  CAS  Google Scholar 

  15. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Béguin S (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 33:4–15

    Article  CAS  Google Scholar 

  16. Mantovani A, Turino T, Lando MG, Gjini K, Byrne CD, Zusi C, Ravaioli F, Colecchia A, Maffeis C, Salvagno G, Lippi G, Bonora E, Targher G (2019) Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab. https://doi.org/10.1016/j.diabet.2019.11.004

  17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612

    Article  Google Scholar 

  18. American Diabetes Association (2019) Microvascular complications and foot care: standards of medical care in diabetes-2019. Diabetes Care 42(suppl 1):S124–S138

    Article  Google Scholar 

  19. Chitongo PB, Roberts LN, Yang L, Patel RK, Lyall R, Luxton R, Aylwin SJB, Arya R (2017) Visceral adiposity is an independent determinant of hypercoagulability as measured by thrombin generation in morbid obesity. TH Open 1:e146–e154

    Article  CAS  Google Scholar 

  20. Pischon T, Hu FB, Girman CJ, Rifai N, Manson JE, Rexrode KM, Rimm EB (2011) Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women. Atherosclerosis 219:322–329

    Article  CAS  Google Scholar 

  21. Yanai H, Yoshida H (2019) beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: mechanisms and perspectives. Int J Mol Sci 20:1190

    Article  CAS  Google Scholar 

  22. Christou GA, Kiortsis DN (2013) Adiponectin and lipoprotein metabolism. Obes Rev 14:939–949

    Article  CAS  Google Scholar 

  23. Restituto P, Colina I, Varo JJ, Varo N (2010) Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome. Am J Physiol Endocrinol Metab 298:E1072–1077

    Article  CAS  Google Scholar 

  24. Chen Y, Zheng Y, Liu L, Lin C, Liao C, Xin L, Zhong S, Cheng Q, Zhang L (2017) Adiponectin inhibits TNF-α-activated PAI-1 expression via the cAMP-PKA-AMPK-NF-κB axis in human umbilical vein endothelial cells. Cell Physiol Biochem 42:2342–2352

    Article  CAS  Google Scholar 

  25. Reiner Ž (2017) Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol 14:401–411

    Article  CAS  Google Scholar 

  26. Nordestgaard BG, Varbo A (2014) Triglycerides and cardiovascular disease. Lancet 384:626–635

    Article  CAS  Google Scholar 

  27. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188

    Article  Google Scholar 

  28. Targher G, Zoppini G, Moghetti P, Day CP (2010) Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver. Semin Thromb Hemost 36:41–48

    Article  CAS  Google Scholar 

  29. Franchini M, Lippi G, Manzato F, Vescovi PP, Targher G (2010) Hemostatic abnormalities in endocrine and metabolic disorders. Eur J Endocrinol 162:439–451

    Article  CAS  Google Scholar 

  30. Mi Y, Yan S, Lu Y, Liang Y, Li C (2016) Venous thromboembolism has the same risk factors as atherosclerosis: a PRISMA-compliant systemic review and meta-analysis. Medicine (Baltimore) 95:e4495

    Article  CAS  Google Scholar 

Download references

Funding

GT is supported in part by Grants from the University School of Medicine of Verona, Verona, Italy.

Author information

Authors and Affiliations

  1. Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Piazzale Stefani, 1, 37126, Verona, Italy

    A. Mantovani, T. Turino & G. Targher

  2. Section of Clinical Biochemistry, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy

    E. Danese, G. L. Salvagno, M. Gelati & G. Lippi

  3. Medical Direction, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy

    C. Bovo

Authors
  1. A. Mantovani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Danese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. L. Salvagno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Gelati
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Turino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Bovo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G. Lippi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Targher
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study concept and design: GL and GT. Acquisition of data: AM, ED, GLS, and MGTT. Analysis and interpretation of data: AM and GT. Drafting of the manuscript: GT and GL. Critical revision of the manuscript for important intellectual contents: all authors study supervision: GT. All authors approved the final submission.

Corresponding author

Correspondence to A. Mantovani.

Ethics declarations

Conflict of interest

The authors have nothing to disclose.

Ethical approval

The study was approved by the University and Azienda Ospedaliera Universitaria Integrata of Verona. All procedures performed in human participants were in accordance with ethical standards of the institutional/national research committee and 1964 Helsinki Declaration and its later amendments.

Informed consent

Informed consent was obtained from all participants.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mantovani, A., Danese, E., Salvagno, G.L. et al. Association between lower plasma adiponectin levels and higher plasma thrombin generation parameters in men with type 2 diabetes: role of plasma triglycerides. J Endocrinol Invest 44, 547–555 (2021). https://doi.org/10.1007/s40618-020-01340-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-020-01340-3

Keywords

Search

Navigation